四川迈锐迪医疗完成数千万元天使轮融资，聚焦肿瘤与神经领域

Core Insights - Sichuan Mairidi Medical Technology Co., Ltd. has completed several million yuan in angel round financing, primarily supported by various investment entities [1][2] - The funding will be used for the development of a high-load nuclear medicine project and the construction of a radioactive drug pilot platform, leveraging microfluidic technology [1][2] Company Overview - Mairidi focuses on innovation in the fields of oncology and neurology, established by teams from Sichuan University and West China Hospital [1][2] - The company aims to overcome existing technological bottlenecks and pioneer the application of microfluidic technology in nuclear medicine [1][2] Technology and Services - The company plans to build a pilot platform for radioactive drug development, providing services such as product concept validation, technical development, and quality research [2][3] - Microfluidic technology offers significant advantages in the separation and purification of radionuclides, which are characterized by low material quantities and high costs [1][2] Industry Context - The nuclear medicine industry is rapidly emerging as a focal point in global healthcare, with therapeutic nuclear drugs already on the market in Europe and the U.S. [2] - Mairidi's investment reflects recognition of the nuclear medicine industry's growth trajectory and the importance of technology transfer from academic institutions [2][3] Future Development - Mairidi will establish core service capabilities in the radioactive drug industry chain, including platforms for radionuclide separation, labeling technology, and molecular modification [3] - The company will equip facilities that meet international standards for the synthesis and quality control of radioactive drugs [3]